A Single-Radial-lmmunodiffusion Technique for the Assay of Rabies Glycoprotein Antigen: Application for Potency Tests of Vaccines Against Rabies
|
|
- Winifred Bond
- 5 years ago
- Views:
Transcription
1 J. gen. Virol. (1982) 59, Printed in Great Britain 197 Key words: rabies/glycoprotein/immunodiffusion/vaccine potency A Single-Radial-lmmunodiffusion Technique for the Assay of Rabies Glycoprotein Antigen: Application for Potency Tests of Vaccines Against Rabies (,4 ccepted 4 No vember 1981) SUMMARY An assay for rabies glycoprotein antigen based on single-radial-immunodiffusion (SRD) is described. Rabies glycoprotein antigen at concentrations of 0.7/lg/ml or greater (approx. l international unit, IU) produced well-defined SRD reaction zones in immunoplates containing antibody to purified glycoprotein. Plots of zone area against relative antigen concentration were linear. The method was found to be of suitable sensitivity for in vitro potency assays of inactivated cell culture rabies vaccines. Qualitative differences were detected between rabies vaccines prepared by two different methods when these were analysed in sucrose gradients for glycoprotein antigen associated with intact virions or in 'soluble' form associated with subviral structures. In vaccines prepared by zonal ultracentrifugation the glycoprotein was totally associated with intact virus, whilst in those prepared by ultrafiltration comparable quantities of subviral antigen were also detected. The SRD test appears to have considerable potential for assays of the antigenic content of rabies vaccines and has the advantage of reducing reliance on conventional in vivo tests for immunogenicity which employ infectious virus. The glycoprotein is the only antigen of the rabies virus particle which is important in stimulating virus-neutralizing antibodies (Cox et al., 1977). Methods to quantify this protein are therefore important for the control and standardization of inactivated rabies vaccines for use in man and animals. Currently, in vivo assays are used routinely to standardize these vaccines. The tests most commonly used are the NIH test (Seligman, 1973) and the Habel test (Habel, 1973). The former involves the immunization of mice with test and reference antigens followed by intracerebral challenge with a standard strain (CVS) of rabies virus. The latter requires the titration of a virus preparation in mice immunized with vaccine and in control mice. These tests are time consuming and have the disadvantage of employing infectious virus, necessitating the use of special containment facilities in certain countries. In addition, potency estimates derived from them show considerable variability (Wiktor et al., 1978; Barth & Jaeger, 1979). There is general agreement (Barth & Jaeger, 1979) that more satisfactory and rapid tests are required for in process control and standardization of rabies vaccines. Barth et al. (1981) have described an antibody-binding test for rabies antigen which gave more reproducible results than in vivo tests but still requires infectious virus. SRD tests have been used for the assay of other inactivated virus vaccines, including influenza (Schild et al, 1975; Wood et al., 1977) and poliovirus (Schild et al., 1980). SRD tests have been adopted internationally for the assay of influenza vaccines enabling reproducible and accurate estimates (coefficient of variation, 5 %) of their haemagglutinin antigen content to be made (Wood et al., 1981). These tests thus appeared to be worthy of evaluation for rabies antigens. For SRD assays with rabies antigens the methods used were essentially those described by Wood et al. (1977). Briefly, potent immune rabbit or sheep serum to purified rabies /82/ $ SGM
2 198 (a) 1:1 Short communications Dilution 1:2 1:4 1:8 4O..-.. N E 30 t~ (b) ' ' ' / I I I i I i i I I I I I I - (c) ~ 2o ~ lo 0 NI 20 l0,i / I I I I 1:4 1:2 3:4 l: Antigen dilution Fraction number Fig. 1. (a) Single-radiai-immunodiffusion assay of rabies virus glycoprotein. Zones were produced by ERA rabies virus glycoprotein (G) and purified ERA rabies virus (V). The undiluted antigens contained 5.6 and 68 gg/ml protein respectively. The gel contained 10 gl/ml gel rabbit anti-era rabies glycoprotein serum. (b) Dose-response curves when dilution is plotted against annulus area for the following: purified ERA virus (D); purified ERA glycoprotein (I); the WHO third international reference preparation for vaccine, an HDCS vaccine concentrated by continuous rate-zonal centrifugation (O); an HDCS vaccine concentrated by ultrafiltration (A). The gel contained 5 gl/ml gel rabbit anti- ERA rabies glycoprotein serum. (c) Distribution of SRD-detectable rabies glycoprotein in sucrose gradients following equilibrium centrifugation of vaccines prepared by rate zonal centrifugation (O) and ultrafiltration (A). The gel contained 5/A/ml gel rabbit anti-era rabies glycoprotein serum. glycoprotein derived from the ERA strain was incorporated in agarose gels [ 1% agarose ME (Marine Colloids) in phosphate-buffered saline (PBS) ph 7.3 with 0.1% NaN 3] which were prepared in perspex moulds on glass plates. Wells (3 or 4 mm diam.) were punched in the gels for the addition of antigen preparations. Antigens for assay were treated with detergent [Mulgofen BC-720, GAF (Great Britain) Ltd.; 2 % final concn., 30 min at room temperature] to release glycoprotein antigen and added to wells in immunoplates in l0 gl or 20 gl volumes. After allowing diffusion for 24 h the gels were washed in PBS for 48 h, dried and stained in
3 Short communications % Coomassie Brilliant Blue to demonstrate zones of antibody-antigen reaction. The diameters of the stained zones were measured using a Transidyne calibration viewer (Transidyne General Corporation, Ann Arbor, Mich., U.S.A.) coupled to Autodata caliper equipment (Autodata, Hitchin, U.K.) Anti-glycoprotein sera were prepared by immunization of animals with purified rabies (ERA) glycoprotein obtained by treatment of purified virus with Triton X- 100 detergent and purified by isoelectric focusing (Dietzschold et al., 1978). This glycoprotein produced a single protein band of mol. wt. approx when examined by electrophoresis on SDSpolyacrylamide gels (Laemmli, 1970). Two or three doses (approx. 20 gg glycoprotein) were given, the first dose with Freund's complete adjuvant, and the animals were bled one week after the final injection. An immune rabbit serum (virus neutralization titre 1:500000) was found satisfactory for use in SRD tests when incorporated in agarose gels at concentrations in the range 5 to 10 /A/ml gel. Studies carried out using an immune sheep serum (5 gl/ml) gave similar results. Well-defined SRD zones were observed when serial dilutions of purified glycoprotein (ERA) were added to the wells of immunoplates (Fig. 1 a). The minimum protein concentration at which visible stained zones were obtained was approx. 0.7 pg/ml. Similar zones were obtained with dilutions of ERA rabies virus which had been purified by gradient centrifugation (Fig. 1 a) and also with the HEP, Pitman-Moore, CVS and Kelev strains of rabies virus (data not shown). When annulus area was plotted against antigen dilution for these preparations linear dose response curves were obtained with the lines meeting at a common intercept on the d 2 axis (Fig. 1 b). These dose-response curves and the position of their intercepts were similar to those previously observed in SRD tests with influenza haemagglutinin (Wood et al., 1977). The relative potency of vaccines with reference to a standard may thus be calculated on the same basis as for influenza vaccines: Vaccine potency = slope of vaccine curve slope of standard curve x potency of standard vaccine Inactivated rabies vaccines for prophylactic and post-exposure treatment of humans in many countries are now derived from human diploid cell strains (HDCS) infected with the Pitman-Moore strain of rabies virus. Vaccines are prepared following concentration of tissue culture fluids by ultrafiltration (Nicolas el al., 1978) or by continuous flow rate-zonal ultracentrifugation (Majer et al., 1978). Current World Health Organization (WHO) recommendations are that vaccines should contain at least 2-5 IU of rabies antigen when compared in the NIH test to the WHO third international reference preparation of rabies vaccine to which has been assigned an arbitrary potency of 10 IU (WHO, 1979). The WHO reference antigen (a lyophilized vaccine prepared by ultracentrifugation) and vaccines prepared from tissue-culture fluid which had been concentrated by ultrafiltration were tested. Typical dose-response curves are shown in Fig. 1 (b). Small but measurable zones were detected when the WHO reference antigen was diluted 1 8. The SRD test thus appeared to be capable of detecting antigen concentrations of approx. I IU and was therefore sufficiently sensitive to evaluate the glycoprotein content of vaccines. In order to investigate whether the glycoprotein antigen was present on intact virus or as free glycoprotein, vaccines were centrifuged in 15 to 55 % sucrose gradients for 2 h at 35 K in the SW41 rotor of the Beckman L5-50 centrifuge. Fractions (0.4 ml) were collected and examined for SRD activity in the presence and absence of detergent. The distribution of SRD activity in samples treated with detergent is shown in Fig. 1 (c). In both types of vaccine a peak of SRD activity was detected at the density corresponding to that of intact rabies virus
4 200 Short communications Table 1. Relationship between antibody responses to rabies vaccine in human volunteers and vaccine potency detected by SRD and NIH test Vaccine potency Antibody responses f ~ r" NIH test SRD test ~" ~ No. of Recipients with post-vaccine titres (IU)* (IU)* (/ag/ml)~" volunteerss; GMT >/5 IU antibody (%) * Estimated by comparison with the third international reference preparation of rabies vaccine (10 IU). Glycoprotein content estimated by comparison with preparation of purified glycoprotein with known protein concentration (Bramhall et al, 1969). $ Adult volunteers received two doses subcutaneously of 1 ml of vaccine prepared as described by Nicolas et al. (1978). Vaccine given at day 0 and day 30, serum samples for antibody assay collected 60 days after first vaccine dose. Serological data kindly provided by Dr A. Nicolas, Merieux Institute, Lyon, France. Antibody titres assessed by mouse neutralization tests in comparison with the WHO international reference preparation of rabies immunoglobulin. particles (1.18 g/ml). No SRD activity was detected in these fractions if detergent treatment was omitted, suggesting that the antigen was associated with intact virus which would not be expected to diffuse in agarose gels. Examination of the fractions by electron microscopy confirmed that intact rabies virus particles were present. For vaccines concentrated by ultrafiltration but not in those prepared by ultracentrifugation, antigen activity was also detected in gradient fractions 22 to 27. This slowly sedimenting antigen was detectable even when treatment of the fractions with detergent was omitted, suggesting that it was associated with subviral particles. The presence of such 'soluble' antigen in tissue culture fluids from which rabies virus has been pelleted has been described previously (Wiktor et al., 1969), but its relevance to vaccine efficacy requires further study. Evidence that the glycoprotein antigen was quantitatively removed from rabies virus particles by treatment with Mulgofen (2 %) was obtained from experiments in which virus particle antigen was detergent-treated and sedimented on sucrose gradients containing 1% Mulgofen. In these studies, all antigen activity detected by SRD resided in fractions 22 to 27. No SRD activity was detected in fractions 13 to 18, corresponding to the sedimentation characteristics of intact virus. For three batches of vaccine prepared following ultrafiltration and tested in our laboratory, SRD potencies varying from 3.5 to 10.5 IU per ml were detected. The glycoprotein content ~g/ml) of these vaccines was calculated from the SRD activity by comparison with a preparation of purified glycoprotein (Table 1). These vaccines were tested in clinical trials involving adult volunteers and antibody responses for each group are shown in Table 1. The results showed correlation between antigenic content of the vaccine detected by SRD and the titre and frequency of antibody responses in vaccines. Our studies indicate that SRD techniques are of potential value for the assay of rabies glycoprotein antigen for research purposes and for the quantitative and qualitative testing of rabies vaccines. SRD tests are rapid and simple and have the advantage that they provide an alternative assay system reducing reliance on the use of animal protection tests employing infectious virus. However, in vitro tests of antigenic content of vaccines do not provide unequivocal evidence of immunogenicity and tests on vaccines should include confirmation of their immunogenicity in animals until considerable satisfactory experience is gained with a given product. The use of reference antigens calibrated in terms of pg/ml of rabies
5 Short communications 201 glycoprotein antigen by biochemical methods would enable rabies vaccine potency to be expressed in defined terms (jug antigen activity per dose) as is the case for inactivated influenza vaccines (Schild et al., 1975), rather than in arbitrary international units. Further information is required on the correlation between antigen content of all available types of vaccines as determined in SRD tests and their immunogenicity in experimental animals and man. Such studies are in progress in our laboratory. Part of this work was carried out when M.F. was a visiting worker at the Wistar Institute, Philadelphia, Pennsylvania, U.S.A. We would like to thank Dr H. Koprowski, Dr T. J. Wiktor and Dr W. H. Wunner of the Wistar Institute for providing the rabbit antiserum, purified ERA rabies glycoprotein and purified rabies virus preparations. We would also like to thank Dr J. Wood, NIBSC for many helpful discussions. Division of Viral Products & WHO Collaborating Centre for Viral Vaccines National Institute for Biological Standards and Control Holly Hill, Hampstead, London NW3 6RB, U.K. REFERENCES MORAG FERGUSON* G.C. SCHILD EARTH, R. & JAEGER, O. (1979). Zur Wirksamkeitspriifung von inaktivierten Tollwut Gewebekulturimpfstoffen im NIH-test. Zentralblatt fffr Bacteriologie Parasitenkunde, Infektionskrankheiten und Hygiene 1 Orig. (B) 169, BARTH, R., GROSS-ALBENHAUSEN, E., JAEGER, O. & MILCKE, L. (1981). The antibody binding test, a useful method for quantitative determination of inactivated rabies virus antigen. Journal of Biological Standardization 9, BRAMHALL, S., NOACK, N., WU, M. & LOEWENBERG, J. R. (1969). A simple calorimetric method for determination of protein. AnalytiealBioehemistry 31, cox, J. H., DIETZSCHOLD, B. & SCHNEIDER, L. G. (1977). Rabies virus glycoprotein. II. Biological and serological characterisation. Infection and Immunity 16, DIETZSCHOLD, B., COX, J. H., SCHNEIDER, L. G., WIKTOR, T. J. & KOPROWSKI, H. (1978). Isolation and purification of a polymeric form of the glycoprotein of rabies virus. Journal of General Virology 40, 13 l-139. HABEL, K. (1973). Habel test for potency. In Laboratory Techniques in Rabies, 3rd edn., pp Edited by M. M. Kaplan & H. Koprowski. Geneva: World Health Organization. LAEMMLI, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, London 227, MAJER, M., HILFENHAUS, J., GRUSCHKAU, H., MAULER, R. & HENNESSEN, W. (1978). A purified human diploid cell rabies vaccine. Developments in Biological Standardization 40, NICOLAS, A. J., PATET, J., VINCENT FALQUET, J. C., BRANCHE, R., DELAITI, P., MONTAGNON, B., PEYRON, L. & SOULEBOT, J. P. (1978). Production of inactivated rabies vaccine for human use on WI38 diploid cells. Results of potency tests. Stability of the vaccine in liquid and freeze-dried forms. Developments in Biological Standardization 40, SCHILD, G. C., WOOD, J. M. & NEWMAN, R. W. (1975). A single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen. Bulletin of the Worm Health Organization 52, SCHILD, O. C., WOOD, J. M., MINOR, P. O., DANDAWATE, C. N. & MAGRATH, D. I. (1980). Immunoassay of poliovirus antigens by single-radial-diffusion: development and characteristics of a sensitive autoradiographic zone size enhancement (ZE) technique. Journal of General Virology 51, SELIGMAN, E. B., JR, (1973). The NIH test for potency. In Laboratory Techniques in Rabies, 3rd edn., pp Edited by M. M. Kaplan & H. Koprowski. Geneva: World Health Organization. WIKTOR, T. J., SOKOL, F., KUWERT, E. & KOPROWSKI, H. (1969). Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proceedings Of the Society for Experimental Biology and Medicine 131, WIKTOR, T. J., ATANASIU, P., BAHMANYAR, M., BOEGEL, K. COX, J. H., D1AZ, A. M, FITZGERALD, E. A., KLrWERT, E, NETI"ER, R., SELIMOV, M., TURNER, O. & VAN STEENIS, G. (1978). Comparison studies on potency tests for rabies vaccine. Developments in Biological Standardization 40, WOOD, J. M., SCHILD, G. C., NEWMAN, R. W. & SEAGROATT, V. (1977). An improved single radial immanodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. Journal of Biological Standardization 5, WOOD, J. M., SEAGROATT, V., SCHILD, G. C., MAYNER, R. E. & ENNIS, F. A. (1981). International collaborative study of single radial diffusion and immunoelectrophoresis techniques for the assay of haemagglutinin antigen of influenza virus. Journal of Biological Standardization 9, WORLD HEALTH ORGANIZATION (1979). Rabies Vaccine. Technical Report Series 638, p. 15. (Received 30 June 1981)
Annex 5. Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories
Annex 5 Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories Abbreviations 262 1. Introduction 262 2. Essential regulatory
More informationNeutralization Epitopes on Poliovirus Type 3 Particles: an Analysis Using Monoclonal Antibodies
J.-gen. Virol. (1984), 65, 197-201. Printed in Great Britain 197 Key words: poliovirus type 3/monoclonal Abs/neutralization/immunoblot Neutralization Epitopes on Poliovirus Type 3 Particles: an Analysis
More informationPreparation and properties of a novel influenza subunit vaccine G. SCHMIDT* H. BACHMAYER E. LIEHL. guinea-pigs, s.c. and i.m. for rabbits.
Postgraduate Medical Journal (June 1976), 52, 360-367. Preparation and properties of a novel influenza subunit vaccine H. BACHMAYER E. LIEHL Ph.D. Ph.D. G. SCHMIDT Ph.D. Summary Haemagglutinin and neuraminidase
More informationStandards and beyond: challenges of application of old methods to next generation products. Elena Semenova, Penny Post, Tim Fields, Manon Cox
Standards and beyond: challenges of application of old methods to next generation products Elena Semenova, Penny Post, Tim Fields, Manon Cox March 25, 2014 Recombinant Flu vaccines Propagation of the influenza
More informationJ. gen. Virol. 098o), 5I, o Printed in Great Britain. t57
J. gen. Virol. 98o), 5I, 157-17o Printed in Great Britain t57 Immunoassay of Poliovirus Antigens by Single-Radial-Diffusion: Development and Characteristics of a Sensitive Autoradiographic Zone Size Enhancement
More informationDifferent Methods. virus inactivated with BPL before concentration. 21/13S) cells (7) and cells of human diploid strain
APPLIED MICoROIOLOGy, July 1972, p. 37-43 Copyright 0 1972 American Society for Microbiology Vol. 24, No. 1 Printed in U.S.A. Recovery of Protective Activity in Rabies Virus Vaccines Concentrated and Purified
More informationLars R. Haaheim ( ) PhD, Professor Emeritus, University of Bergen, Norway
Lars R. Haaheim (1945-2011) PhD, Professor Emeritus, University of Bergen, Norway Licensing requirements a personal perspective John M Wood Summer School on Influenza, Siena August 1-5 2011 National Institute
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ehrlich HJ, Müller M, Oh HML, et al. A clinical trial of a
More informationImmobilized Virions, and Mixed Hemadsorption
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1977, p. 346-352 Copyright 1977 American Society for Microbiology Vol. 5, No. 3 Printed in U.S.A. New Tests for Characterization of Mumps Virus Antibodies: Hemolysis
More informationAnimal model for testing human Ascaris allergens
J. Biosci., Vol. 3 Number 1, March 1981, pp. 77-82. Printed in India. Animal model for testing human Ascaris allergens KRISHNA MUKERJI*, R. P. SAXENA, S. N. GHATAK and K. C. SAXENA Division of Biochemistry,
More informationCharacterization by Western Blotting of the lmmunogens of Infectious Bursal Disease Virus
J. gen. Virol. (1985), 66, 1479-1488. Printed in Great Britain 1479 Key words: IB D virus/ immunogens/polypeptides Characterization by Western Blotting of the lmmunogens of Infectious Bursal Disease Virus
More informationCorrelates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer
Correlates of Protection for Flu vaccines and Assays Overview by Simona Piccirella, PhD Chief Executive Officer Company Overview: VisMederi is an Italian private small enterprise established in 2009 and
More informationIMMUNOGENICITY AND FEASIBILITY OF PURIFIED CHICK EMBRYO CELL VACCINE
IMMUNOGENICITY AND FEASIBILITY OF PURIFIED CHICK EMBRYO CELL VACCINE S. Sehgal M. Bhardwaj D. Bhattacharya ABSTRACT Two hundred seventy-one children reported at the WHO Collaborative Centre for Rabies
More informationAstrovirus-associated gastroenteritis in children
Journal of Clinical Pathology, 1978, 31, 939-943 Astrovirus-associated gastroenteritis in children C. R. ASHLEY, E. 0. CAUL, AND W. K. PAVER1 From the Public Health Laboratory, Myrtle Road, Bristol BS2
More informationDr Laszlo Palkonyay World Health Organization
International Proficiency Study of the Single Radial Immuno Diffusion Test (SRID) for Influenza Vaccine Manufacturers and Regulators from Developing Countries Dr Laszlo Palkonyay World Health Organization
More informationDetection of antibodies of the IgM class in sera
J. clin Path., 1976, 29, 423-427 Detection of antibodies of the gm class in sera of patients recently infected with influenza viruses YVONNE. BUCHNER, R. B. HEATH, J. V. COLLNS, AND J. R. PATTSON From
More informationApplication of the Single Radial Diffusion Test for Assay of
JOURNAL OF CUNICAL MICROBIOLOGY, Dec. 1975, p. 531-540 Copyright 1975 American Society for Microbiology Vol. 2. No. 6 Printed in U.S.A. Application of the Single Radial Diffusion Test for Assay of Antibody
More informationUltrastructure of Mycoplasmatales Virus laidlawii x
J. gen. Virol. (1972), I6, 215-22I Printed in Great Britain 2I 5 Ultrastructure of Mycoplasmatales Virus laidlawii x By JUDY BRUCE, R. N. GOURLAY, AND D. J. GARWES R. HULL* Agricultural Research Council,
More informationPRODUCT INFORMATION & MANUAL
PRODUCT INFORMATION & MANUAL 0.4 micron for Overall Exosome Isolation (Cell Media) NBP2-49826 For research use only. Not for diagnostic or therapeutic procedures. www.novusbio.com - P: 303.730.1950 - P:
More informationIsolation of Influenza C Virus from Pigs and Experimental Infection of Pigs with Influenza C Virus
J. gen. Virol. (1983), 64, 177-182. Printed in Great Britain 177 Key words: influenza C virus/antibodies/pigs Isolation of Influenza C Virus from Pigs and Experimental Infection of Pigs with Influenza
More informationAmino Acid Composition of Polypeptides from Influenza Virus Particles
J. gen. Virol. 0972), x7, 61-67 Printed in Great Britain 6x Amino Acid Composition of Polypeptides from Influenza Virus Particles By W. G. LAVER AND NICOLA BAKER Department of Microbiology, The John Curtin
More informationHepatitis Virus. Omaha, Nebraska to the tubes. The cell sheets were observed after 48 and 72 hr. The titer was calculated by the Reed-
APPr1u MICROBIOLOGY, Nov. 1970, p. 667-671 Copyright 1970 American Society for Microbiology Vol. 20, No. 5 Printed in U.S.A. Continuous-Flow Ultracentrifugation of Canine Distemper Virus and Infectious
More informationImmunologic Cross-Reaction Between Luteinizing Hormone and Human Chorionic Gonadotropin
Immunologic Cross-Reaction Between Luteinizing Hormone and Human Chorionic Gonadotropin MELVIN L. TAYMOR, M.D., DONALD A. GOSS, M.D., and ALBERT BUYTENDORP, M.D. RECENTLY a number of reports 2 4 have indicated
More informationG. W. WOOD J. C. MUSKETT and D. H. THORNTON MAFF, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, U.K.
J. Comp. Path. 1986 vol. 96 OBSERVATIONS ON THE ABILITY OF AVIAN REOVIRUS VACCINMATION OF HENS TO PROTECT THEIR PROGENY AGAINST THE EFFECTS OF CHALLENGE WITH HOMOLOGOUS AND HETEROLOGOUS STRAINS By G. W.
More informationEstimations of the Molecular Weight of the Influenza Virus Genome
o r. gem Viral. &97I), H, Io3-Io9 103 Printed in Great Britain Estimations of the Molecular Weight of the Influenza Virus Genome By J. J. SKEHEL National Institute for Medical Research, Mill Hill, London
More informationEthylenediaminetetraacetate
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, June 1980, p. 1148-1153 0099-2240/80/06-1148/06$02.00/0 Vol. 39, No. 6 Comparative Study on the Mechanisms of Rotavirus Inactivation by Sodium Dodecyl Sulfate and
More informationHARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES
3AB14a HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES Guideline Title Harmonisation of Requirements for Influenza Vaccines Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationWHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationRabies Subunit Vaccines
J. gen. Virol. (1983), 64, 1649-1656. Printed in Great Britain 1649 Key words: rabies virus/glycoprotein/peptide fragments REVIEW ARTICLE Rabies Subunit Vaccines By WILLIAM H. WUNNER,* BERNHARD DIETZSCHOLD,
More informationColumn chromatography for the development of pandemic and seasonal influenza vaccines
Column chromatography for the development of pandemic and seasonal influenza vaccines Olga Chervyakova Research Institute for Biological Safety Problems, RK ME&S 5 th Meeting with International Partners
More informationThe Glycoprotein of Vesicular Stomatitis Virus Is the Antigen That Gives Rise to and Reacts with Neutralizing Antibody
JOURNAL OF VIROLOGY, Dec. 1972, p. 1231-1235 Copyright 1972 American Society for Microbiology Vol. 10, No. 6. Printed in U.S.A. The Glycoprotein of Vesicular Stomatitis Virus Is the Antigen That Gives
More informationAcid Stability of Hepatitis A Virus
J. gen. Virol. (1989), 70, 2481-2485 Printed in Great Britain 2481 Key words: acid stability~hepatitis A virus/enteroviruses Acid Stability of Hepatitis A Virus By ELKE SCHOLZ, URSULA HEINRICY AND BERTRAM
More informationProduction of Interferon Alpha by Dengue Virus-infected Human Monocytes
J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS
More informationExplanation on immunological assays
Explanation on immunological assays Single Radial Diffusion Single radial difussion (SRD) is an immunodiffusion technique used in immunology to determine the quantity of an antigen. Typically, wells are
More informationThe Infectious Cycle. Lecture 2 Biology W3310/4310 Virology Spring You know my methods, Watson --SIR ARTHUR CONAN DOYLE
The Infectious Cycle Lecture 2 Biology W3310/4310 Virology Spring 2016 You know my methods, Watson --SIR ARTHUR CONAN DOYLE The Infectious Cycle Virologists divide the infectious cycle into steps to facilitate
More informationHIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates
HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
More informationIntestinal Trypsin Can Significantly Modify Antigenic Properties of Polioviruses: Implications for the Use of Inactivated Poliovirus Vaccine
JOURNAL OF VIROLOGY, Dec. 1987, p. 3749-3753 22-538X/87/123749-5$2./ Copyright C 1987, American Society for Microbiology Vol. 61, No. 12 Intestinal Trypsin Can Significantly Modify Antigenic Properties
More informationhowever, and the present communication is concerned with some of
THE AGGLUTINATION OF HUMAN ERYTHROCYTES MODIFIED BY TREATMENT WITH NEWCASTLE DISEASE AND INFLUENZA VIRUS' ALFRED L. FLORMAN' Pediatric Service and Division of Bacteriology, The Mount Sinai Hospital, New
More informationTRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells
Journal of Supramolecular Structure 4:441 (401)-447 (407) (1976) TRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells
More informationAntigenic Analysis of Isolated Polypeptides from Visna Virus
INFECTION AND IMMUNITY, June 1976, p. 1728-1732 Copyright 1976 American Society for Microbiology Vol. 13, No. 6 Printed in USA. Antigenic Analysis of Isolated Polypeptides from Visna Virus P. D. MEHTA,*
More informationNEUTRALIZATION OF REOVIRUS: THE GENE RESPONSIBLE FOR THE NEUTRALIZATION ANTIGEN* BY HOWARD L. WEINER~ AN~ BERNARD N. FIELDS
NEUTRALIZATION OF REOVIRUS: THE GENE RESPONSIBLE FOR THE NEUTRALIZATION ANTIGEN* BY HOWARD L. WEINER~ AN~ BERNARD N. FIELDS (From the Department of Microbiology and Molecular Genetics, Harvard Medical
More informationQuality, safety and standards for poliomyelitis vaccines
Quality, safety and standards for poliomyelitis vaccines 7 th WHO/UNICEF consultation Geneva, 30 October 2008 Jackie Fournier-Caruana, WHO/QSS 1 Expert Committee on Biological Standardization The ECBS
More informationPHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Human coagulation factor IX PHARMACOPOEIA MONOGRAPH PM.3.3.2.0004.15 First Edition The present Pharmacopoeia Monograph applies to human coagulation factor IX
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Purification and biochemical properties of SDS-stable low molecular weight alkaline serine protease from Citrullus Colocynthis Muhammad Bashir Khan, 1,3 Hidayatullah khan, 2 Muhammad
More informationImmunological Cross-Reactivities of Woodchuck and Hepatitis
INFECTION AND IMMUNITY, Feb. 1982, p. 752-757 0019-9567/82/020752-06$02.00/0 Vol. 35, No. 2 Immunological Cross-Reactivities of Woodchuck and Hepatitis B Viral Antigens IRVING MILLMAN,* THERESA HALBHERR,
More informationInactivation of Influenza B Virus by Normal Guinea-pig Serum
J. gen. Virol. (1987), 68, 1135-1141. Printed in Great Britain 1135 Key words: influenza B virus/inhibitor/guinea-pig serum Inactivation of Influenza B Virus by Normal Guinea-pig Serum ByFUMIYAMAMOTO,
More informationAn Immunological Study of Avian, Viral and Bacterial Neurarninidase Based on Specific Inhibition of Enzyme by Antibody
J. gen. Microbiol. (1963), 32, 225-233 Printed in Great Britain 225 An Immunological Study of Avian, Viral and Bacterial Neurarninidase Based on Specific Inhibition of Enzyme by Antibody BY G. L. ADA AND
More informationAnnex 3 Recommendations for the production and control of influenza vaccine (inactivated)
World Health Organization WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated) Recommendations published by WHO are intended
More informationRecommendations to assure the quality, safety and efficacy of acellular pertussis vaccines
Annex 4 Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines Replacement of Annex 2 of WHO Technical Report Series, No. 878 Introduction 189 Background 189 Scope 191
More informationMengovirus Virions. growth (48-h cultures) were infected with a. cell at a density of 107 cells per ml of ABM42-
JOURNAL OF VIROLOGY, Mar. 1977, p. 1256-1261 Copyright 1977 American Society for Microbiology Vol. 21, No. 3 Printed in U.S.A. Factors Affecting Composition and Thermostability of Mengovirus Virions CLIFFORD
More informationHAROLD S. M.S. Georgia the administration of large doses of the appropriate. IN a previous study (Kaye, Dowdle & McQueen,
Postgraduate Medical Journal (March 1973) 49, 152-158. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation STEVEN R. STEPHEN C. M.D.
More informationRG12T. For In Vitro Diagnostic Use. Passive Particle-Agglutination Test for Detection of Antibodies to HTLV-
RG12T Read this insert carefully before performing the assay and keep for future reference. The reliability of assay procedures other than those described in this package insert cannot be guaranteed. For
More informationDevelopment of influenza vaccine production by means of chromatographic methods
Development of influenza vaccine production by means of chromatographic methods WHO meeting on prospects for influenza vaccine technology transfer to vaccine manufacturers of developing countries. 27-28
More informationSTUDIES OF THE HEMAGGLUTININ OF HAEMOPHILUS PERTUSSIS HIDEO FUKUMI, HISASHI SHIMAZAKI, SADAO KOBAYASHI AND TATSUJI UCHIDA
STUDIES OF THE HEMAGGLUTININ OF HAEMOPHILUS PERTUSSIS HIDEO FUKUMI, HISASHI SHIMAZAKI, SADAO KOBAYASHI AND TATSUJI UCHIDA The National Institute of Health, Tokyo, Japan (Received: August 3rd, 1953) INTRODUCTION
More informationEXPERIMENTAL INFECTION OF HUMAN VOLUNTEERS WITH THE U-VIRUS-A STRAIN OF ECHO
[ 274 ] EXPERIMENTAL INFECTION OF HUMAN VOLUNTEERS WITH THE U-VIRUS-A STRAIN OF ECHO VIRUS TYPE 11 BY F. E. BUCKLAND, M. L. BYNOE, L. PHILIPSON* AND D. A. J. TYRRELL The Common Cold Research Unit, Salisbury,
More informationUpdate of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines 28 May 2009 Introduction This document updates WHO guidance 1 to national
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 12 March 1997 CPMP/BWP/214/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON HARMONISATION
More informationTwo More Small RNA Viruses from Honey Bees and Further Observations on Sacbrood and Acute Bee-Paralysis Viruses
J. gen. ViroL (t977), 37, 175-182 I75 Printed in Great Britain Two More Small RNA Viruses from Honey Bees and Further Observations on Sacbrood and Acute Bee-Paralysis Viruses By L. BAILEY AND R. D. WOODS
More informationavailable in the United Kingdom. Introduction Antigenic variation in its surface antigens (haemagglutinin and
Antigenic Variants of Influenza B Virus PAPERS AND ORIGINALS G. C. SCHILD, MARGUERITE S. PEREIRA, PRATIMA CHAKRAVERTY, W. R. DOWDLE, W. K. CHANG British Medical journal, 1973, 4, 127-131 Summary From 1967
More informationInactivation of Poliovirus I (Brunhilde) Single Particles by Chlorine in Water
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Aug. 198, p. 381-385 99-224/8/8-381/5$2./ Vol. 4, No. 2 Inactivation of Poliovirus I (Brunhilde) Single Particles by Chlorine in Water D. G. SHARP* AND JENNY LEONG
More informationViral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
More informationEffect of Mutation in Immunodominant Neutralization Epitopes on the Antigenicity of Rotavirus SA-11
J. gen. Virol. (1985), 66, 2375-2381. Printed in Great Britain 2375 Key words: rotaviruses/antigenieity/antiserum selection Effect of Mutation in Immunodominant Neutralization Epitopes on the Antigenicity
More informationAnalysis of Viral and Defective-Interfering Nucleocapsids in Acute and Persistent Infection by Rhabdoviruses
J. gen. Virol. (1982), 60, 87-97. Printed in Great Britain 87 Key words: nucleocapsms/persistence/dlparticles/rabies Analysis of Viral and Defective-Interfering Nucleocapsids in Acute and Persistent Infection
More informationImmunological evaluation of nextgeneration. Othmar G Engelhardt
Immunological evaluation of nextgeneration influenza vaccines Othmar G Engelhardt Today s presentation Evaluation of current influenza vaccines European regulatory guidelines Evaluation of novel vaccines
More informationGladstone Institutes, University of California (UCSF), San Francisco, USA
Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24 Gag Marianne Gesner, Mekhala Maiti, Robert Grant and Marielle Cavrois * Gladstone Institutes, University of
More informationRabies virus-like particles expressed in HEK293 cells
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Rabies virus-like particles expressed in HEK293 cells Diego Fontana Cell Culture Laboratory
More informationComparison of Swine Vesicular Disease Virus and Coxsackie B5 Virus by Serological and RNA Hybridization Methods
J. gen. Virol. (I976), 31, 231-237 Printed in Great Britain 23I Comparison of Swine Vesicular Disease Virus and Coxsackie B5 Virus by Serological and RNA Hybridization Methods By F. BROWN, T. F. WILD,
More informationNew Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
More informationImmunity to influenza in ferrets
J. Hyg., Camb. (1974), 72, 91 91 Printed in Great Britain II. Immunity to influenza in ferrets Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets
More informationWHO International Biological Reference Preparations Held and distributed by the WHO International Laboratories for Biological Standards
WHO International Biological Preparations Anthrax spore vaccine. Lyophilized spore suspension of Bacillus anthracis strain 34 F2. 1 IU / ampoule. Anti-brucella abortus serum, bovine. Lyophilized. 1,000
More informationAvian Infectious Bronchitis Vaccine, Inactivated
Avian Infectious Bronchitis Vaccine, Inactivated Avian Infectious Bronchitis Vaccine, Inactivated consists of an emulsion or a suspension of one or more serotypes of avian infectious bronchitis virus which
More informationThe Assay of Influenza Antineuraminidase Activity by an Elution Inhibition Technique
3.. gen. Virol. (1977), 34, 137-I44 Printed in Great Britain 137 The Assay of Influenza Antineuraminidase Activity by an Elution Inhibition Technique By G. APPLEYARD AND J. D. ORAM Microbiological Research
More informationFormation of an Infectious Virus-Antibody Complex with Rous
JOURNAL OF VIROLOGY, Mar. 1976, p. 163-167 Copyright 1976 American Society for Microbiology Vol. 17, No. 3 Printed in U.S.A. Formation of an Infectious Virus-Antibody Complex with Rous Sarcoma Virus and
More informationAntigenic Characterization of Measles and SSPE Virus Haemagglutinin by Monoclonal Antibodies
J. gen. Virol. (1981), 57, 357-364. Printed in Great Britain 357 Key words: measles/morbillivirus/monoclonal antibody Antigenic Characterization of Measles and SSPE Virus Haemagglutinin by Monoclonal Antibodies
More informationConcentration and Purification of Influenza Virus on Insoluble Polyelectrolytes
APPEuw MicRoBIoLoGY, Apr. 1972, p. 740-744 Copyright 0 1972 American Society for Microbiology Vol. 23, No. 4 Printed in U.S.A. Concentration and Purification of Influenza Virus on Insoluble Polyelectrolytes
More informationSynthesis of Proteins in Cells Infected with Herpesvirus,
Proceedings of the National Academy of Science8 Vol. 66, No. 3, pp. 799-806, July 1970 Synthesis of Proteins in Cells Infected with Herpesvirus, VI. Characterization of the Proteins of the Viral Membrane*
More informationThe Protective Antigen of a Highly Immunogenic Strain of Clostridium chauvoei Including an Evaluation of Its Flagella as a Protective Antigen
128 Journal of General Microbiology (1974), 84, 128-134 Printed in Great Britain The Protective Antigen of a Highly Immunogenic Strain of Clostridium chauvoei Including an Evaluation of Its Flagella as
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON
More informationBY F. BROWN, B. CARTWRIGHT AND DOREEN L. STEWART Research Institute (Animal Virus Diseases), Pirbright, Surrey. (Received 22 August 1962) SUMMARY
J. gen. Microbial. (1963), 31, 179186 Prinied in Great Britain 179 The Effect of Various Inactivating Agents on the Viral and Ribonucleic Acid Infectivities of FootandMouth Disease Virus and on its Attachment
More informationShort duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine
Brazilian Antibody Journal titers after of Medical rabies vaccination and Biological Research (1998) 31: 1275-1280 ISSN 0100-879X Short Communication 1275 Short duration of neutralizing antibody titers
More informationReagents for the Typing of Human Influenza Isolates 2011
Reagents for the Typing of Human Influenza Isolates 2011 This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for Reference
More informationDepleting Lipoproteins from Serum
Depleting Lipoproteins from Serum Kathy K. Foxx Kalen Biomedical LLC President For decades, fetal bovine serum (FBS) has been used as a supplement for cell-culture media, providing the growth factors that
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationSIV p27 ANTIGEN CAPTURE ASSAY
SIV p27 ANTIGEN CAPTURE ASSAY Enzyme Immunoassay for the detection of Simian Immunodeficiency Virus (SIV) p27 in tissue culture media Catalog #5436 and #5450 Version 6; 12/2012 ABL PRODUCTS AND SERVICES
More informationAn evaluation of two new haemagglutination tests for the rapid diagnosis of autoimmune thyroid diseases
Journal of Clinical Pathology, 1978, 31, 1147-115 An evaluation of two new haemagglutination tests for the rapid diagnosis of autoimmune thyroid diseases I. CAYZER, S. R. CHALMERS, D. DONIACH', AND G.
More informationIn the Name of God. Talat Mokhtari-Azad Director of National Influenza Center
In the Name of God Overview of influenza laboratory diagnostic technology: advantages and disadvantages of each test available Talat Mokhtari-Azad Director of National Influenza Center Tehran- Iran 1 1)
More informationANTIBODY RESPONSES TO ANTIGENIC DETERMINANTS OF INFLUENZA VIRUS HEMAGGLUTININ
Published Online: 1 December, 1974 Supp Info: http://doi.org/10.1084/jem.140.6.1559 Downloaded from jem.rupress.org on January 8, 2019 ANTIBODY RESPONSES TO ANTIGENIC DETERMINANTS OF INFLUENZA VIRUS HEMAGGLUTININ
More informationGenomic Alterations Associated with Persistent Infections by Equine Infectious Anaemia Virus, a Retrovirus
J. gen. Virol. (1984), 65, 1395-1399. Printed in Great Britain 1395 Key words: EIA V/retrovirus persistence~antigenic variation/oligonucleotide mapping Genomic Alterations Associated with Persistent Infections
More informationVariation in the HindlII Restriction Fragments of DNA from the Chinese Tian Tan Strain of Vaccinia Virus
J. gen. irol. (1985), 66, 1819-1823. Printed in Great Britain 1819 Key words: vaccinia virus~vaccine~restriction Jragrnent variation ariation in the Hindl Restriction Fragments of DNA from the Chinese
More informationEMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
More informationNori Rabbit IL-2 ELISA Kit DataSheet
Nori Rabbit IL-2 ELISA Kit DataSheet IL-2 is an interleukin, a type of cytokine immune system signaling molecule. IL-2 is a T cell stimulatory cytokine best known for inducing T cell proliferation, the
More informationOverview of assays for influenza vaccines immunology evaluation
Overview of assays for influenza vaccines immunology evaluation Emanuele Montomoli BSc; MSc; MBiochem Professor in Public Health University of Siena ITALY Lab. of Molecular Epidemiology University of Siena
More informationElectron Microscope Studies of HeLa Cells Infected with Herpes Virus
244 STOKER, M. G. P., SMITH, K. M. & Ross, R. W. (1958). J. gen. Microbiol. 19,244-249 Electron Microscope Studies of HeLa Cells Infected with Herpes Virus BY M: G. P. STOKER, K. M. SMITH AND R. W. ROSS
More informationEXOTESTTM. ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids
DATA SHEET EXOTESTTM ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids INTRODUCTION Exosomes are small endosome-derived lipid nanoparticles
More informationDetection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity
Borgis New Med 2015; 19(4): 147-155 DOI: 10.5604/14270994.1191796 Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity *Mónika Rózsa 1, István Jankovics
More informationSIV p27 Antigen ELISA Catalog Number:
INTENDED USE The RETRO-TEK SIV p27 Antigen ELISA is for research use only and is not intended for in vitro diagnostic use. The RETRO-TEK SIV p27 Antigen ELISA is an enzyme linked immunoassay used to detect
More informationAli Alabbadi. Bann. Bann. Dr. Belal
31 Ali Alabbadi Bann Bann Dr. Belal Topics to be discussed in this sheet: Particles-to-PFU Single-step and multi-step growth cycles Multiplicity of infection (MOI) Physical measurements of virus particles
More informationBacterial expression of a VLP Sub-unit for rapid and cheap influenza vaccination
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-23-2012 Bacterial expression of a VLP Sub-unit for rapid and cheap influenza vaccination Anton Middelberg
More information